TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06206031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraosseous ultrasonography at tibia before, during, and after a physiological vascular stimulation (venous occlusions, arterial occlusion, handgrip)
Description: Timing for sub-protocol 1 (performed twice with 2-to-10-day interval): donning in supine position - rest 5 minutes - venous occlusion to 40 mmHg 3 minutes - rest 10 minutes - arterial occlusion to 200mmHg 2 minutes - post-occlusion period 10 minutes - rest 10 minutes - static handgrip 30% Maximum Voluntary Force 3 minutes - recovery 2 minutes and doffing.~Timing for sub-protocol 2 (performed once). First, two sequences of intraosseous ultrasonography are performed in 45° head-up tilt position, with 10-minutes rest between sequences: donning and rest 5 minutes - occlusion to 80 mmHg 2 minutes - rest 10 minutes - occlusion to 180 mmHg 2 minutes - rest 10 minutes. During the first sequence, ultrasonography probe is positioned between middle and lower third of tibia for cortical bone measurement; during the second - at distal epiphysis of the tibia for trabecular bone measurement. After ultrasonography, subject is sitting down for 10 minutes for computed tomography.
Study: NCT05935735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia (BBTI)
Description: 4 in-person sessions; 1 individual and 3 group sessions
Study: NCT06387264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Adhesive
Description: Medical Adhesive (produced by Beijing Compont Medical Devices Co., Ltd.) For varicose veins in the main saphenous vein, use 0.1 ml glue for every 3 cm of blood vessels.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClosureFast Endovenous Radiofrequency Ablation(RFA) Catheter
Description: ClosureFast Endovenous Radiofrequency Ablation (RFA) Catheter (produced by America Medtronic Inc.) The ClosureFast catheter precisely heats a 7 cm vein segment in one 20-second interval.
Study: NCT06245941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105 tablets
Description: TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3909 tablets
Description: TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3909 tablets
Description: TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.
Study: NCT06289101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text4FATHER
Description: Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
Study: NCT06570577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inter-semispinalis Plane Block
Description: A nerve block targeting the dorsal rami of the cervical spinal nerves can help alleviate postoperative incisional pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Routine Pain Management
Study: NCT04214535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tritanium C Anterior Cervical Cage
Description: 50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Anterior Cage for one or two-levels
Study: NCT05621070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS002
Description: JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JS002
Description: JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.
Study: NCT06366217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MydCombi Device
Description: ophthalmic spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MydCombi Drug
Description: Tropicamide 1% and phenylephrine HCl 2.5%
Study: NCT05616624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: -Given 60 minutes (+/- 15 minutes) prior to docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: -Given 60 minutes (+/- 15 minutes) prior to docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: -Given 60 minutes (+/- 15 minutes) prior to docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: -Given over the course of 90 minutes (+/- 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: -Given over the course of 90 minutes (+/- 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: -Given over the course of 90 minutes (+/- 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: -Given over the course of 60 minutes (+/- 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: -Given over the course of 60 minutes (+/- 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: -Given over the course of 60 minutes (+/- 10 minutes)
Study: NCT06513858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communal Drumming
Description: Communal drumming

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communal drumming recordings
Description: Recordings of drumming taken from the music made during a previous component of the study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communal drumming recordings
Description: Recordings of drumming taken from the music made during a previous component of the study
Study: NCT05156047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label pitolisant
Description: Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-blind placebo
Description: Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double-blind pitolisant
Description: Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.
Study: NCT05884307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trans Care Web App
Description: an educational and interactive website designed to improve coping strategies of TNB individuals
Study: NCT06221280

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: Group E: While performing the erector spina plan block; Patients are placed in the lateral decubitus position, aseptic conditions are provided, the spinous process in the midline is determined under ultrasonography guidance, and the transverse process is determined 3 cm laterally from the T11 level. 100 mm 22G block needle erector.~Group T: The lumbar petit region will be determined and placed on the lateral abdominal wall at the mid-axillary line, between the iliac crest and the lower costal arch, via a linear probe (12-15 MHz probe). After determining the internal oblique muscle as the thickest muscle and the transversus abdominis muscle as the thinnest muscle, a 100 mm 22 G needle will be placed in the same plane as the USG probe (in-plane or long axis technique). The progress of the needle will be observed on ultrasound along with the facial click sensation. After the second click sensation is felt between the internal oblique and transversalis fascia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: Group E: While performing the erector spina plan block; Patients are placed in the lateral decubitus position, aseptic conditions are provided, the spinous process in the midline is determined under ultrasonography guidance, and the transverse process is determined 3 cm laterally from the T11 level. 100 mm 22G block needle erector.~Group T: The lumbar petit region will be determined and placed on the lateral abdominal wall at the mid-axillary line, between the iliac crest and the lower costal arch, via a linear probe (12-15 MHz probe). After determining the internal oblique muscle as the thickest muscle and the transversus abdominis muscle as the thinnest muscle, a 100 mm 22 G needle will be placed in the same plane as the USG probe (in-plane or long axis technique). The progress of the needle will be observed on ultrasound along with the facial click sensation. After the second click sensation is felt between the internal oblique and transversalis fascia.
Study: NCT04851691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR CDS
Description: When a clinician initiates a new antipsychotic prescription for a patient with dementia, a three-pronged electronic health record clinical decision support tool pops up: (1) Alerting clinicians that antipsychotic prescriptions increase patient mortality; (2) Offering non-pharmacological behavioral resources for caregivers via a link to the IDEA! strategy resources on how caregivers can best manage a patient's behavioral disturbance non-pharmacologically, which will be available in the EHR to include in the patient's after visit summary; and (3) Defaulting prescriptions to a low supply of pills in to order to minimize harm. In addition, the PI will email all providers randomized to the intervention arm in order to make them aware of the components of this intervention and its motivation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patients will receive usual care from their physicians.
Study: NCT06296849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive Treatment (FIT)
Description: In the present study, the investigators will provide financial incentives of $200 for biochemically verified abstinence at each of three time points (1 month, 3 month, and 6 month) following baseline. Additionally, the investigators will provide a bonus of $200 for participants who demonstrate abstinence at each of the time points. This incentive value is consistent with recent research using macro-level financial incentives and incorporates both short-term and long-term incentives to shape behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive Treatment (FIT)
Description: In the present study, the investigators will provide financial incentives of $200 for biochemically verified abstinence at each of three time points (1 month, 3 month, and 6 month) following baseline. Additionally, the investigators will provide a bonus of $200 for participants who demonstrate abstinence at each of the time points. This incentive value is consistent with recent research using macro-level financial incentives and incorporates both short-term and long-term incentives to shape behavior.
Study: NCT05414500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Administered IV
Study: NCT05880979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engaging Together for Healthy Relationships
Description: A comprehensive parent-adolescent dating violence prevention intervention designed to be provider delivered within the context of a pediatric well-child visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular well child care
Description: Participants will receive their regularly scheduled well-child care
Study: NCT06513910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants in dyads will be positioned across from each other while listening to various types of music (i.e. music that is harmonically-intact and music in which the harmonic content has been randomly scrambled).
Study: NCT06235515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation program
Description: conventional treatment (hotpack and TENS and exercise)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation program
Description: conventional treatment (hotpack and TENS and exercise)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: virtual reality treatment
Study: NCT05315414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrimeTaper EV implant
Description: Tapered dental implant developed by Dentsply Sirona
Study: NCT05516537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidelines for Exercise in Multiple Sclerosis (GEMS)
Description: Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: FLEX Stretching and Toning Program
Description: Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.
Study: NCT04986072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: Half of participants will receive Intravenous Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose solution
Description: Half of participants will receive intravenous 5% Dextrose solution for 4 hours.
Study: NCT04956796

Intervention type: BEHAVIORAL
Intervention: Airway Video Library Training
Description: A video airway library consisting of real-life clinical videos of laryngoscopy and endotracheal intubation was developed by the study investigators. This library consists of video clips of normal and easy airways, pediatric airways as well as pathological or difficult airways that is devoid of patient identifying data. The participants of the study group will be exposed to the video library by two learning sessions. Each learning session consists of 1 hour of interactive \& immersive learning of 30 airway videos. At the end of the session, the participants will be oriented to the airway and identify key airway structures, learn to troubleshoot and navigate difficult anatomy, optimize visualization, and use accessory airway equipment.

Intervention type: BEHAVIORAL
Intervention: Airway Video Library Training
Description: A video airway library consisting of real-life clinical videos of laryngoscopy and endotracheal intubation was developed by the study investigators. This library consists of video clips of normal and easy airways, pediatric airways as well as pathological or difficult airways that is devoid of patient identifying data. The participants of the study group will be exposed to the video library by two learning sessions. Each learning session consists of 1 hour of interactive \& immersive learning of 30 airway videos. At the end of the session, the participants will be oriented to the airway and identify key airway structures, learn to troubleshoot and navigate difficult anatomy, optimize visualization, and use accessory airway equipment.

Intervention type: BEHAVIORAL
Intervention: Conventional Airway Training
Description: The endotracheal intubation training Anesthesiology students currently receive routinely as part of their education.

Intervention type: BEHAVIORAL
Intervention: Conventional Airway Training
Description: The endotracheal intubation training Anesthesiology students currently receive routinely as part of their education.
Study: NCT04784325

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw through TAP II
Description: Two self-administered blood draws through TAP II device

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw through ADx cardT
Description: One self-administered ADx card blood draw

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw through standard venipuncture
Description: One phlebotomist-performed standard venipuncture
Study: NCT06567145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Enhancement Cognitive Therapy (NECT)
Description: The Narrative Enhancement and Cognitive Therapy (NECT) consists of 20 group sessions divided into five parts: orientation (2 sessions), psychoeducation on stigma (3 sessions), cognitive restructuring (7 sessions), narrative enhancement (7 sessions), and a concluding reflection (1 session). The program helps participants challenge self-stigmatizing beliefs, develop coping skills, and create a new, positive narrative about themselves. Each session lasts about an hour, with a structured format of introduction, main discussion, and conclusion, encouraging active participation and reflection on personal experiences. The intervention ultimately fosters self-efficacy, control, and hope for the future.
Study: NCT04944277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ThoughtFullChat Application
Description: A subscription-based mobile platform that empowers users to proactively engage with their mental health via self-serve tools and 1-on-1 daily bite-sized coaching with certified mental health professionals.
Study: NCT04592042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feel-Good- Group
Description: Eight sessions of group intervention focussing on information on emotion regulation, training of emotion regulation techniques and mindfulness.
Study: NCT05564416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study: NCT05852119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient treatment with standard anticoagulant therapy
Description: All patients included in the study will be treated on an outpatient basis, that is, they will be discharged within the first 24 hours of the diagnosis of PE in the Emergency Department.
Study: NCT05889104

Intervention type: OTHER
Group type: OTHER
Intervention: Randomization Program
Description: The subjects in the Control Group will undergo twelve weeks of low impact Aerobics Training along with a health awareness program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Loading Protocol (PLP):
Description: he subjects in the Progressive Loading Group will undergo 4-7 days of moderate to high impact loading activities per week.
Study: NCT05225038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will meet with an exercise physiologist to undergo evaluation and develop individualized regimens for prehabilitation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional
Description: Participants will meet with a nutritionist to undergo evaluation and develop individualized regimens for prehabilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Medicine
Description: Participants will have 1 appointment with behavioral medicine - all participants will meet with the same behavioral medicine specialist to ensure consistency. Participants will receive education regarding factors that affect postoperative recovery and relaxation techniques.~Participants will also have the option to request faith support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Medicine
Description: Participants will have 1 appointment with behavioral medicine - all participants will meet with the same behavioral medicine specialist to ensure consistency. Participants will receive education regarding factors that affect postoperative recovery and relaxation techniques.~Participants will also have the option to request faith support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Participants who are actively smoking will be counseled regarding smoking cessation during their preoperative appointment with a member of the surgical team. They will also be offered a referral to smoking cessation resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: Participants who are actively smoking will be counseled regarding smoking cessation during their preoperative appointment with a member of the surgical team. They will also be offered a referral to smoking cessation resources.
Study: NCT05556473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-(2-[18F]FLUOROETHYL)-L-Tryptophan
Description: Radioactive tracer 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.
Study: NCT05564416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study: NCT04989751

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Electromyography (EMG) would be used at the baseline for dignoisis and furtue analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: IDEAL MRI
Description: Muscle-speciifc sequences (e.g. IDEAL) would be used to scan patients at baseline and follow-up stages to characterize the fat fraction and atrophy in different muscles.
Study: NCT04777851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib in combination with pembrolizumab
Description: Randomized patients will receive regorafenib at a dose of 90 mg per day by mouth on days 1 to 21 of a 28-day cycle, in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 (D1) of a 6-week cycle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Loco-regional therapy
Description: Patients will be treated with TACE or TARE on-demand according to site's standard of practice.
Study: NCT05879185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb23104
Description: XmAb23104 (10 mg/kg) intravenously on days 1 and 15 of each 28-day cycle. XmAb23104 will be administered by IV infusion at a constant rate over 1 hour.